AstraZeneca approaches Gilead about potential merger

AstraZeneca has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest healthcare deal on record.

AstraZeneca, valued at $140 billion, is the U.K.’s biggest drugmaker by market capitalization and has developed treatments for conditions including cancer and cardiovascular disease. Gilead, worth $96 billion at Friday’s close, is the creator of a drug that has received U.S. approval for use with coronavirus patients.

Shares of AstraZeneca have risen about 41% over the last 12 months. Shares of Gilead gained about 19% over the period.

AstraZeneca has been claiming for years that they could turn things around without a major purchase or merger..Wall St was skeptical - AstraZeneca approaches Gilead about potential merger

Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen

Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.

AstraZeneca approached Gilead about potential merger - Bloomberg NewsAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger, Bloomberg News reported on Sunday, citing people familiar with the matter. Hope combined R&D could expedite coronavirus vaccine. That's an interesting news, but it may be too early Of course they did. THE ONLY ONES GETTING RICHER WHILE THE POOR BECOMES MORE IMPOVERISHED....
Herkunft: Reuters - 🏆 2. / 97 Weiterlesen »

AstraZeneca approached Gilead about potential merger - Bloomberg NewsAstraZeneca Plc has approached rival drugmaker Gilead Sciences Inc about a potential merger, Bloomberg News reported on Sunday, citing people familiar with the matter. Hope combined R&D could expedite coronavirus vaccine. That's an interesting news, but it may be too early Of course they did. THE ONLY ONES GETTING RICHER WHILE THE POOR BECOMES MORE IMPOVERISHED....
Herkunft: Reuters - 🏆 2. / 97 Weiterlesen »